Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Phase I Clinical Study of Safety，Tolerability， Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Cytotoxic T Lymphocyte Antigen 4 Single Domain Antibody Fc Fusion Protein Injection in Subjects With Advanced Solid Tumors

This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN044 in participants with all advanced solid tumors who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of KN044 as a single agent in adult participants with advanced solid tumors.

Study Overview

• Status: Recruiting
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Biological: KN044

Detailed Description

This study will involve patients and follow the standard "3 + 3"design. KN044 will be antimedical intravenously over 30 minutes with planned doses of 0.03, 0.1, 0.3, 1, 3, 6,10 mg/kg Once every 3 weeks for first 4 doses, then every 3, or 6, or 12 weeks for up to 1 year if no intolerable toxicities occur and per agreement with investigator antimedical monitor based on emerging data.

• Study Type: Interventional
• Enrollment (Estimated): 39
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Shiqi Bai; Phone Number: 18943642700; Email: baishiqi@intelli-crown.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100000
      • Recruiting
      • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      • Contact: Rui Chen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subjects can understand informed consent, voluntarily participate and sign informed consent.
2. Tumor subject type Clinical diagnosis of advanced malignant tumors. Patients diagnosed by pathology and/or cytology; malignant melanoma, patients with advanced renal cell carcinoma, colorectal cancer, lung cancer, breast cancer, prostate cancer, etc. are preferred; the inclusion of melanoma is pathological and / or cytologically undiagnosed unresectable patients with stage 3b/3c or stage 4 (M1a / M1b) melanoma, in which patients with stage IV M1b have to meet the following requirements: no more than 5; the longest path of a single lesion must not exceed 20 mm; the sum of the longest diameters of the cumulative lesions must not exceed 50 mm.
3. Subjects with locally advanced (non-resectable) and / or metastatic solid tumor that has progressed after standard therapies or no standard therapy exists.
4. Previous anti-tumor therapy (including endocrine chemoradiotherapy/radiotherapy, targeted therapy) ended more than 4 weeks and has been restored to baseline or ≤ grade 1 from previous adverse events following [Common Criteria for Assessment of Adverse Events (CTCAE) version 5.0] (except for patients with hair loss).
5. 18-75 years of age, male or female; 10)Eastern Cooperative Oncology Group score 0 or 2; Life expectancy ≥ 3 months.
6. Previous major surgery ≥1 month ago.

7. Must have adequate organ function, prior to start of KN044, including the following:

   1. white blood cell count ≥ 3.0 × 109 / L;
   2. absolute neutrophil count (ANC) ≥ 1.5 ×109/L;
   3. platelet count ≥ 100 × 109/L;
   4. hemoglobin ≥ 9 g/dL
   5. serum albumin ≥ 2.5 g / dL;
   6. Hepatic: total bilirubin ≤ 1.5 times the upper limit of normal (ULN); aspartate transaminase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5× ULN (≤5 × ULN if with liver involvement)
   7. Renal: Serum creatinine ≤ 1.5×ULN or 24-hour Estimated clearance≥50 mL / min (Cockcroft and Gault formula);
   8. Coagulation tests International standardization ratio (INR) ≤ 1.5, prothrombin time (PT), activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
8. Normal left ventricular ejection fraction (LVEF) ≥50% measured by multigated radionuclide angiography or Echocardiography.
9. Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception within at least eight months from the screening period to five half-lives after the last treatment. These measures include, but are not limited to, oral or implantable injections of hormonal contraceptives; intrauterine birth control ring or placement of hormone-releasing intrauterine device); or use of barrier methods such as condoms or septum and spermicide products.
10. According to ResponseEvaluationCriteriainSolid Tumors Version1.1, the subject should have an assessable lesion (target lesion or non-target lesion)
11. grade ≤ 2 peripheral neuropathy can be enrolled

Exclusion Criteria:

1. At the discretion of the investigator, there are both serious medical conditions that may harm the safety of the subject or affect the subject's completion of the study, including but not limited to: severe heart disease, cerebrovascular disease, uncontrolled diabetes, Insulin dependent diabetes, serious infection;Thyroid disease
2. Accepted any other anti-tumor drug therapies, or other immunological anti-tumor treatments, including but not limited to PD-1/L1 inhibitors before the first KN044 dosing.
3. Pregnant or nursing females
4. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure New York Heart Association III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, ECG QT interval（fridericia)> 450msec, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia)；Hypertension (defined as sustained systolic blood pressure> 150 mm Hg and / or post-diastolic blood pressure with antihypertensive drugs> 100 mm Hg;
5. suffering from mental disorders, infectious diseases, and skin diseases that are difficult to control;
6. Known active hepatitis B or C or known infection with HIV .
7. History of life-threatening hypersensitivity, or known to be allergic to protein drugs or recombinant proteins or any ingredients in KN044 drug formulation
8. Known severe bleeding factors that can affect venous blood sampling;
9. Acute or chronic uncontrolled renal disease, pancreatitis or liver disease (per investigator assessment).
10. Subjects with active autoimmune disease or a documented medical history of autoimmune disease or symptoms that require systemic use of steroid and/or immunosuppressant. Exceptions are subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by replacement therapy.
11. Use of more than 15 mg of prednisone or equivalent dose of steroids per day within 3 months of administration.
12. Electrocardiogram QT interval (fridericia) > 450 msec and severe arrhythmia requiring medication (except for atrial fibrillation or paroxysmal supraventricular tachycardia);

13. Uncontrolled primary central nervous system tumors or central nervous system metastasis; based on screening brain magnetic resonance imaging (MRI), patients who have one of the following may not be excluded:

    1. No evidence of brain metastases or has to be clinically stable for at least 4 weeks
    2. Untreated brain metastases not needing immediate local therapy
14. Live vaccines are banned 30 days prior to enrollment and during clinical studies. Inactive vaccines are allowed during the study;
15. Within 30 days prior to screening, the patient has undergone any other experimental drug therapy or has participated in another interventional clinical trial;
16. The study may not be completed for other reasons or the Investigators believes that it should not be included;
17. Peripheral neuropathy >Grade 2.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KN044 0.03 mg/kg dose group; KN044 0.03 mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Experimental: KN044 0.1 mg/kg dose group; KN044 0.1 mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Experimental: KN044 0.3mg/kg dose group; KN044 0.3mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Experimental: KN044 1 mg/kg dose group; KN044 1 mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Experimental: KN044 3 mg/kg dose group; KN044 3 mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Experimental: KN044 6mg/kg dose group; KN044 6mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.
Experimental: KN044 10mg/kg dose group; KN044 10mg/kg dose group,once every 3 weeks，a total of four cycles	Biological: KN044; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose-limiting toxicity for The maximum tolerated dose	Dose-limiting toxicity observation period 6 weeks after the first dose	up to 6 weeks
KN044 of adverse event	the adverse events are recorded according to the actual occurrence	through study completion, an average of 210 days
KN044 of abnormalities of physical findings and laboratory tests,	The data of the clinical research center is collected and analyzed according to the time point of the test flow chart	through study completion, an average of 210 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK parameters: Area under curve (AUC)	According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.	an average of 126 days
PK parameters: Cmax	According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.	an average of 126 days
PK parameters: Clearance rate (CL)	According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.	an average of 126 days
PK parameters: t1/2	According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.	an average of 126 days
PK parameters: Vss	According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.	an average of 126 days
PK parameters: dose proportionality	According to the test schedule, the blood volume of each subject's PK was analyzed and PK analysis was performed.	an average of 126 days
Incidence of the positive anti-drug antibodies and titers of anti-drug antibodies	According to the test schedule, the blood volume of each subject's anti-drug antibodies was analyzed and anti-drug antibodies analysis was performed.	an average of 147 days
Anti-tumor activity as measured by ResponseEvaluationCriteriainSolidTumors Version1.1(RESISTv1.1)	Evaluation of tumor response according to RESISTv1.1 criteria, complete relief（CR), Partial relief(PR), Stable disease(SD), PD、ORR[CR＋PR]）、Disease control rate(DCR[CR＋PR＋SD]）、PFS、DOR	During the treatment period , the tumor was evaluated every 6 weeks, then every 9 weeks.

Collaborators and Investigators

• Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD
• Investigators: Principal Investigator: Chunmei Bai, Peking Union Medical College Hospital; Principal Investigator: Rui Chen, Peking Union Medical College Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2020
• Primary Completion (Estimated): June 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: October 10, 2019
• First Submitted That Met QC Criteria: October 11, 2019
• First Posted (Actual): October 15, 2019

Study Record Updates

• Last Update Posted (Actual): September 1, 2023
• Last Update Submitted That Met QC Criteria: August 30, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Anti-Drug Antibodies; Adverse Event; Complete Response
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: KN0440101a

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No